AgomAb Therapeutics (NASDAQ:AGMB) Director Purchases $88,800.00 in Stock

Key Points

• Director David Epstein purchased 10,000 AGMB shares at an average price of $8.88, investing $88,800 and increasing his direct ownership by 66.67% to 25,000 shares.
• AgomAb shares fell 0.8% to $9.04, near the lower end of their 52-week range, while the company reported a quarterly loss of $0.46 per share and analysts expect a full-year loss of $1.77 per share.
• Analyst sentiment remains positive, with eight Buy ratings and one Hold rating producing a Moderate Buy consensus and an average price target of $37.50, substantially above the current share price.

AgomAb Therapeutics NV (NASDAQ:AGMB - Get Free Report) Director David Epstein bought 10,000 shares of the company's stock in a transaction dated Wednesday, October 21st. The stock was bought at an average cost of $8.88 per share, with a total value of $88,800.00. Following the acquisition, the director directly owned 25,000 shares of the company's stock, valued at approximately $222,000. The trade was a 66.67% increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.

AgomAb Therapeutics Trading Down 0.8%

Shares of AGMB traded down $0.07 during mid-day trading on Thursday, reaching $9.04. The company had a trading volume of 10,126 shares, compared to its average volume of 135,952. The company's 50 day simple moving average is $11.70 and its 200 day simple moving average is $11.78. AgomAb Therapeutics NV has a 1-year low of $7.92 and a 1-year high of $17.82.

AgomAb Therapeutics (NASDAQ:AGMB - Get Free Report) last released its quarterly earnings data on Thursday, August 6th. The company reported ($0.46) earnings per share (EPS) for the quarter. Equities research analysts predict that AgomAb Therapeutics NV will post -1.77 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently weighed in on AGMB shares. Johnson Rice restated a "buy" rating on shares of AgomAb Therapeutics in a research report on Wednesday. Cantor Fitzgerald initiated coverage on shares of AgomAb Therapeutics in a research report on Wednesday, August 19th. They set an "overweight" rating on the stock. Piper Sandler started coverage on shares of AgomAb Therapeutics in a report on Tuesday, August 25th. They set an "overweight" rating and a $60.00 target price on the stock. HC Wainwright restated a "buy" rating on shares of AgomAb Therapeutics in a research report on Wednesday. Finally, B. Riley Financial assumed coverage on shares of AgomAb Therapeutics in a research report on Thursday, July 23rd. They issued a "buy" rating and a $34.00 price target for the company. Eight investment analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company. Based on data from MarketBeat, AgomAb Therapeutics presently has a consensus rating of "Moderate Buy" and a consensus target price of $37.50.

AgomAb Therapeutics Company Profile

Agomab Therapeutics N.V. is a clinical-stage biotechnology company developing antibody-based medicines designed to activate biological pathways involved in tissue repair and regeneration. The company focuses on serious diseases in which restoring or rebuilding damaged tissue could provide therapeutic benefit.

Agomab's lead program, AGMB-129, is an investigational, gut-restricted agonist of fibroblast growth factor receptor 1c (FGFR1c) being developed for inflammatory bowel disease, including Crohn's disease.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.